Navigation Links
FDA approves MyocondaR IND for MAP in Crohn's Disease

SYDNEY, Australia 24 April 2007. Giaconda Ltd (ASX: GIA) today announced that the US Food and Drug Administration (FDA) has approved the Company's Investigational New Drug application (IND) for the clinical development of MyocondaR to treat patients with Crohn's Disease infected with Mycobacterium avium spp paratuberculosis (MAP).

The Company understands that its lead product, MyocondaR, is the first therapy to be submitted to the FDA for this indication. There are no anti-MAP therapies approved for use in Crohn's Disease.

MAP is considered as the most likely infectious cause of Crohn's Disease. Current treatments on the market are indicated for symptomatic treatment of the disease. On the basis of clinical experience, Giaconda believes that by treating and controlling the underlying MAP infection, MyocondaR will offer a valuable therapy to patients who do not respond to currently available therapies. Current research indicates that between 40 - 50% of Crohn's patients are MAP positive.

Patients can be diagnosed with MAP infection using a blood test. The IND approval allows the Company to commence the next clinical trial of MyocondaR in the USA. The Company is continuing preparations for the multi-centre, double blind, placebo controlled, Phase II/III trial. Before the trial commences the Company will conduct pharmacokinetics investigations, test the drug manufacturing for the trial and make ethics submissions to the various clinical trial centres. It is anticipated that the trial will commence by the end of 2007.

Since the previous Phase III trial, which was undertaken prior to Giaconda acquiring MyocondaR, an alternative development program, substantially different from its predecessor, has been undertaken based on further understanding of the mechanism of action of MyocondaR. This has resulted in a new product based on the original research. The Phase II/III trial is necessary due to the changes in the drug form
'"/>




Page: 1 2 3 4

Related medicine technology :

1. FDA approves IND on Lead Product M6G
2. ChemoCentryx Presents Positive Phase 2 Clinical Data for Traficet-EN in Crohns Disease at the Digestive Disease Week 2007 Conference
3. Enzo Biochem Individualized Oral Immune Regulation Therapy May Be Effective Approach to Treating Crohns Disease
4. UCB Presents Long-Term CImzia Data in Crohns Disease
5. New Analysis of Data Shows Treatment With Abbotts Humira (Adalimumab) Significantly Reduced Disease-Related Hospitalization for Patients with Crohns Disease
6. Appendicitis: Evolving Tools to Diagnose a Classic Disease
7. Non-Invasive Diagnostic Tests for Celiac Disease
8. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. Samaritans Alzheimers Drug Caprospinol Suggests Brain May be Able to Heal From Alzheimers Disease
11. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: FDA approves MyocondaR IND for MAP Crohn Disease
(Date:8/3/2015)... (Nasdaq: DRRX ) announced today financial results for the ... net loss was $5.5 million for the three months ended ... million and net loss of $5.5 million for the three ... cash and investments of $37.8 million, compared to cash and ... 30, 2015, we had $19.8 million in long term debt. ...
(Date:8/3/2015)... 2015 Par Pharmaceutical Companies, Inc. announced today ... August 7, 2015 at 9:00 a.m. EDT to review ... June 30, 2015.  Par is privately held and currently ... its filings with the Securities and Exchange Commission and ... by following the instructions at http://www.parpharm.com/financialinfo .  Par ...
(Date:8/3/2015)... YORK , Aug. 3, 2015   ... global pharmaceutical company Allergan plc is ... Deloitte and Intermountain Healthcare to include ... harness ConvergeHEALTH,s OutcomesMiner analytics platform to generate real-world ... outcomes. "We look forward to expanding ...
Breaking Medicine Technology:DURECT Corporation Announces Second Quarter 2015 Financial Results and Update of Programs 2DURECT Corporation Announces Second Quarter 2015 Financial Results and Update of Programs 3DURECT Corporation Announces Second Quarter 2015 Financial Results and Update of Programs 4DURECT Corporation Announces Second Quarter 2015 Financial Results and Update of Programs 5DURECT Corporation Announces Second Quarter 2015 Financial Results and Update of Programs 6DURECT Corporation Announces Second Quarter 2015 Financial Results and Update of Programs 7DURECT Corporation Announces Second Quarter 2015 Financial Results and Update of Programs 8DURECT Corporation Announces Second Quarter 2015 Financial Results and Update of Programs 9DURECT Corporation Announces Second Quarter 2015 Financial Results and Update of Programs 10ConvergeHEALTH by Deloitte and Intermountain Healthcare Expand Real World Evidence Collaboration with Allergan to Focus on Women's Health 2ConvergeHEALTH by Deloitte and Intermountain Healthcare Expand Real World Evidence Collaboration with Allergan to Focus on Women's Health 3ConvergeHEALTH by Deloitte and Intermountain Healthcare Expand Real World Evidence Collaboration with Allergan to Focus on Women's Health 4
... RAPIDS, Mich., May 31, 2011 The Neuroblastoma ... the opening of a first-of-its-kind genomic-based clinical trial ... relapsed and refractory neuroblastoma. The ... (VARI), is a nationwide network of pediatric cancer ...
... Life Technologies Corporation  (NASDAQ: LIFE ) today ... RNA-Seq Kit for the Ion Personal Genome Machine (PGM™) ... to microarrays for transcript expression analysis. The Ion PGM ... enabling scientists to get far more accurate and comprehensive ...
Cached Medicine Technology:Consortium Opens Landmark Personalized Medicine Children's Cancer Trial 2Ion Torrent Ships New RNA Sequencing Application as Fast, Easy, Affordable Alternative to Microarrays 2Ion Torrent Ships New RNA Sequencing Application as Fast, Easy, Affordable Alternative to Microarrays 3Ion Torrent Ships New RNA Sequencing Application as Fast, Easy, Affordable Alternative to Microarrays 4
(Date:8/4/2015)... ... 2015 , ... Mr Didier Cauchois, CIO of information systems ... , Mr Cauchois attributes the success to the dedication from the team at ... technology offered by Winscribe's platform. , "We have already begun to see ...
(Date:8/3/2015)... ... August 04, 2015 , ... The ... a 2015-2016 inductee into the NAPW VIP Woman of the Year Circle. She ... 700,000 members and over 200 operating Local Chapters, NAPW is the nation’s leading ...
(Date:8/3/2015)... ... August 04, 2015 , ... The American ... , The new internationally peer-reviewed Guidelines were prepared by members of the AAT ... imaging, in evaluating patients with dental-oral and systemic health-related complaints. , Thermography ...
(Date:8/3/2015)... , ... August 03, 2015 , ... sweetFrog Enterprises, LLC. ... location is the 20th sweetFrog store operating in the Lone Star State. The premium ... growing companies in 2014. , The store, located at 2916 US-75, Sherman, TX 38652, ...
(Date:8/3/2015)... ... August 03, 2015 , ... The Workgroup for Electronic Data Interchange ( ... create efficiencies in healthcare information exchange, announced the release of its findings from its ... Services (HHS) Secretary, WEDI shared survey results and recommendations , strongly ...
Breaking Medicine News(10 mins):Health News:The Oscar Lambret Center (France) Completes First Stage Of Winscribe Text Rollout 2Health News:The Oscar Lambret Center (France) Completes First Stage Of Winscribe Text Rollout 3Health News:The Oscar Lambret Center (France) Completes First Stage Of Winscribe Text Rollout 4Health News:National Association of Professional Women Inducts Armethia Holt, CEO at AA&G Group Homes, LLC, Into its VIP Woman of the Year Circle 2Health News:American Academy of Thermology (AAT) Publishes First-Ever Guidelines for Oral-Systemic Thermography 2Health News:American Academy of Thermology (AAT) Publishes First-Ever Guidelines for Oral-Systemic Thermography 3Health News:sweetFrog Reopens Texas Store Today 2Health News:WEDI ICD-10 Survey Results: Industry Nearing Readiness but Physician Practices Lagging Behind 2Health News:WEDI ICD-10 Survey Results: Industry Nearing Readiness but Physician Practices Lagging Behind 3Health News:WEDI ICD-10 Survey Results: Industry Nearing Readiness but Physician Practices Lagging Behind 4
... of altruism; helping others ... one,s own health issues, CHICAGO, May 15 Meet Cindy Zamirowski, ... "cancer,free" thumbs up from her physician, stepped off the curb to raise ... The Bolingbrook mom of three and grandma of three rallied her ...
... to a new study from the University of Minnesota, the ... have been identified. The researchers found that the point of ... in receptor molecules, molecular "hooks" on the outer surface of ... of the bloodstream. The research appears in the May 15 ...
... ORLANDO, FL, May 20, 2008- Maxi-K gene therapy may ... whose erectile dysfunction (ED) is not treatable with oral ... Scientific Meeting of the American Urological Association (AUA) may ... to reporters in a special press conference on May ...
... FL, May 20, 2008 Transplantation of muscle-derived ... treatment for patients suffering from urinary incontinence following ... the 103rd Annual Scientific Meeting of the American ... resulting from iatrogenic sphincter damage may benefit from ...
... May 21, 2008Men aged 75-80 with prostate-specific antigen (PSA) ... discontinue their regular prostate cancer screenings, according to new ... the American Urological Association (AUA). Johns Hopkins University researchers ... a PSA level of 3 ng/ml or above had ...
... U.S. Hospitals, ANN ARBOR, Mich., May 14 ... 13 hospitals for excellence in,performance improvement at the ... the 2008 awards were announced during the Thomson,Reuters ... Resort,in Orlando, Florida., Temple University Health System ...
Cached Medicine News:Health News:After Effects: Giving Back Is Good for You 2Health News:U of Minnesota researcher discovers the starting point of sun-induced skin cancer 2Health News:AUA 2008: Maxi-K gene transfer may prove to be safe and effective erectile dysfunction treatment 2Health News:Regular prostate-specific antigen screening may be discontinued in certain elderly populations 2Health News:Thomson Reuters Honors Temple University Health System for Initiative That Cut Costs $64 Million and Grew Clinical Service Lines 2
... semiconductor-based laser system representing the latest in technological ... for fast treatment of large areas (14 mm ... High power and large spot size optimize laser ... indicated for the treatment of vascular and pigmented ...
The Perkins has been established for well over 20 years as a "world standard" for hand held applanation tonometers....
The new TOPCON 8800 Series of auto refractors and auto kerato-refractors satisfies the needs of today's demanding eyecare practice !...
... TruFlow™ Oxygen flowmeter with a Lexan®inner calibrated ... calibration and manufacturing defects. A wide range ... needs. Also available with all popular inlet ... and double unit configurations. Our extra large ...
Medicine Products: